Fatty Acid Composition of Current IVLEs

current IVLEs

The ω-6:ω-3 fatty acid ratio in Smoflipid® has not been shown to improve clinical outcomes compared to other intravenous lipid emulsions.



EPA/DHA

  • Smoflipid® has been shown to improve EPA and DHA levels in adult patients7,23
    – ESPEN states, "Addition of EPA and DHA to lipid emulsions has demonstrable effects on cell membranes and inflammatory processes." (Grade B)21

α-tocopherol

  • An additive in Smoflipid® that prevents the oxidation of lipids in the formulation (~200 mg/L)7,18,23
    – In clinical studies, Smoflipid® has been shown to increase plasma α-tocopherol levels7,18,23

References

  1. Klek S, et al. Four-week parenteral nutrition using a third generation lipid emulsion (SMOFlipid): a double-blind, randomised, multicentre study in adults. Clin Nutr. 2013;32(2):224-231.
  1. Smoflipid [prescribing information].
  1. Intralipid [prescribing information].
  2. Nutrilipid [prescribing information].
  3. Antébi H, et al. Liver function and plasma antioxidant status in intensive care unit patients requiring total parenteral nutrition: comparison of 2 fat emulsions. JPEN J Parenter Enteral Nutr. 2004;28(3):142-148.
  1. Singer P, et al. ESPEN Guidelines on Parenteral Nutrition: intensive care. Clin Nutr. 2009;28(4):387-400.
  1. Grimm H, et al. Improved fatty acid and leukotriene pattern with a novel lipid emulsion in surgical patients. Eur J Nutr. 2006;45(1):55-60.